On May 3, 2022 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that the company will host a conference call and live webcast on Monday, May 9, 2022 at 4:30 p.m. ET to report first quarter 2022 financial results and discuss recent business highlights (Press release, Heron Therapeutics, MAY 3, 2022, View Source [SID1234613392]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call can be accessed by dialing 1-844-825-9789 for domestic callers and 1-412-317-5180 for international callers. Please provide the operator with the passcode 10166891 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron’s website for 60 days following the call.

On May 3, 2022 Fresenius Kabi and the U.S. based company Cerus Corporation reported that it signed a new agreement for the production of systems for pathogen inactivation in blood components (Press release, Fresenius, MAY 3, 2022, View Source [SID1234613391]). The collaboration will help expanding access to pathogen-reduced blood components to patients. For many years, Cerus and Fresenius Kabi have collaborated regarding medical products specializing in pathogen inactivation for platelets and plasma. Since market launch of Cerus’ INTERCEPT systems, more than 11 million units have been in use worldwide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 3, 2022 Eli Lilly and Company (NYSE: LLY) reported that it will attend the Bank of America Securities 2022 Healthcare Conference, May 10-11, 2022 (Press release, Eli Lilly, MAY 3, 2022, View Source [SID1234613390]). Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat on Tuesday, May 10 at 7:40 p.m., Eastern time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

On May 3, 2022 Curium reported it has successfully enrolled and dosed patients in the ECLIPSE Trial. ECLIPSE is a Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus standard of care hormone therapy in patients with metastatic castration-resistant prostate cancer (Press release, Curium, MAY 3, 2022, View Source [SID1234613389]). The clinical trial is enrolling patients at sites across the U.S. and will be opening clinical trial sites in Europe in 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to see the ECLIPSE clinical trial progress with patients enrolled and treated with 177Lu-PSMA-I&T," said Renaud Dehareng, Curium’s Group CEO. "We are dedicated to redefining the experience of cancer through our trusted legacy in nuclear medicine. The ECLIPSE clinical trial demonstrates our commitment to patients with metastatic castration-resistant prostate cancer in North America and Europe."

"We would like to thank the investigators and healthcare providers at the clinical trial sites for their dedication to patients with metastatic castration-resistant prostate cancer," said Sakir Mutevelic, MD, Curium’s Chief Medical Officer. "Through our collaboration, we are working together to determine the safety and efficacy of this potential new investigational treatment for patients in need."

For more information about the ECLIPSE Trial, visit Curium’s Clinical Trial website or contact Curium’s Clinical Trial team directly at [email protected] with questions or to locate a clinical trial site near you.

On May 3, 2022 CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, reported that it will report its financial results for the first quarter ended March 31, 2022, after the market close on Thursday, May 12, 2022, and will host a corporate update conference call at 4:30pm Eastern Time (Press release, CorMedix, MAY 3, 2022, View Source [SID1234613388]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!